TORL Biotherapeutics LLC announced that it will receive $158,300,000 in funding on April 4, 2024. The company will issue membership units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.56 USD | -1.85% | -4.75% | -17.00% |
05:12pm | Bristol Myers: national schizophrenia campaign | CF |
02:34pm | Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.00% | 87.9B | |
+38.06% | 705B | |
+32.82% | 583B | |
-3.54% | 364B | |
+20.25% | 332B | |
+5.21% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.88% | 169B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it expects to receive $158.3 million in funding